

Poster ID	<b>Monday November 14</b>	
2	Blood Neutrophil-to-Lymphocyte Ratio Correlates With Tumor Prognosis in Patients With papillary Thyroid Cancer	Peiyong Li, Dept of nuclear medicine, Ruijin Hospital, School of Medicine, Shanghai Jiaotong University, CN
8	Production and Quality control of Indium-111 Pentetreotide (OctreoScan™) radiopharmaceutical in Iran	Seyed Yousef Fazaeli Hoseini Nezhad, Nuclear science and Technology Research Institute (NSTRI), IR
11	HIGH DOSE RADIOACTIVE IODINE THERAPY (CAPSULE VERSUS SOLUTION) OF DIFFERENTIATED THYROID CARCINOMA IN MYANMAR: A VERY PRIMITIVE THERAGNOSTICS	KHIN PA PA MYO, MINISTRY OF HEALTH, MM
13	Recurrent well differentiated thyroid carcinoma – prognosis and clinical outcome	Faria Nasreen, National Institute of Nuclear Medicine & Allied Sciences, Dhaka, BD
20	A Sn-117m Electroplated Cholangiocarcinoma Stent	Gilbert R. Gonzales, R-NAV, LLC, US
26	Clinical and histopathological characteristics of Differentiated Thyroid Carcinoma among paediatric population and its treatment outcome	Phay Phay Khor, Hospital Kuala Lumpur, MY
27	Tissue Polypeptide Specific Antigen (TPS ) Estimation as Noninvasive Aid to Personalised Management of Cancer Cervix.	PADMAMALIKA HAZRA, ST JOHN'S COLLEGE, AGRA, IN
31	Outcome of radioiodine therapy in Hürthle cell carcinoma of thyroid – A tertiary centre experience.	RAIHAN HUSSAIN, National Institute of Nuclear Medicine and Allied Sciences, BAEC, BD
38	ROLE OF FDG PET/CT IN PATIENTS WITH DIFFERENTIATED THYROID CANCER WITH NEGATIVE I-131 WHOLE BODY SCAN AND ELEVATED THYROGLOBULIN	THI MINH CHAU TRINH, Nuclear Medicine Department, Faculty of Medicine, HCMC National University, VN
41	Sn-117m colloid radiosynoviorthesis effects on canine OA synovitis as evaluated by PET, MRI and behavioral measures	Cynthia A Doerr, R-NAV, LLC, US
43	Effects of Thyroxine Withdrawal in Patients with Differentiated Thyroid Cancer	SAYEDUR RAHMAN MIAH, Institute of Nuclear Medicine & Allied Sciences, Comilla. Bangladesh Atomic Energy Commission., BD
57	Challenges and opportunities in the localization of Radiopharmaceuticals	Gregory Çiocson, Philippine Nuclear Research Institute, PH
59	Efficacy of Radioiodine Treatment in Well-differentiated Thyroid Cancer in Children	Emerita Barrenechea, St Luke's Medical Center, PH
60	THYROGLOBULINE ELEVATED BUT NEGATIVE IODINE SCINTIGRAPHY (TENIS) SYNDROME: AN ANALYSIS OF THE DATA OF 79 PATIENTS WITH RESPECT TO MULTIPLE RISK FACTORS AND 18F FDG PET-CT FINDINGS	Jayanta Das, Tata Medical Center, IN
62	PRRT in Medullary Thyroid Cancer	Gheorghe Anka, Medical University of Innsbruck, AT
64	PET-CT Imaging in Differentiated Thyroid Carcinoma Patients with Rising Serum Tg/Anti Tg Antibody	Sadia Sultana, National Institute of Nuclear Medicine & Allied Sciences, BD

Poster ID	<b>Tuesday, November 15</b>	
4	Development of a New Drug Carrier for Radiopharmaceuticals based on DTPA-Functionalized Nano-porous MCM-41 Silica for theranostics applications	Seyed Yousef Fazaeli Hoseini Nezhad, Nuclear science and Technology Research Institute (NSTRI), IR
5	synthesis, radiolabeling and pre eliminary biological evaluation of bis-(2-methyl8-hydroxy quinoline)-Copper-64 complex as a potential theranostic agent	Seyed Yousef Fazaeli Hoseini Nezhad, Nuclear science and Technology Research Institute (NSTRI), IR
7	Gallium-68/67 radiolabeled radachlorin complexes: novel Theranostic agents based on PET &PDT	Seyed Yousef Fazaeli Hoseini Nezhad, Nuclear science and Technology Research Institute (NSTRI), IR
9	Synthesis of the radiolabeled complex, Tris-(2-methyl8-hydroxy quinoline)- Gallium-67 (67Ga-HMQ) as a potential nuclear imaging agent	Seyed Yousef Fazaeli Hoseini Nezhad, Nuclear science and Technology Research Institute (NSTRI), IR
17	Stability and efficacy of a therapeutic dose of Lu-Dotatate prepared at a remote centralized Radiopharmacy: the initial clinical results [Work in progress]	Masha Maharaj, Umhlanga Molecular Imaging and therapy, ZA
21	Radionuclide Bone Pain Palliation in Breast Cancer Metastasis	Raluca Mititelu, Central Universitary Emergency Military Hospital Bucharest, RO
29	PSMA Radioligand Therapy (PRLT) using Lu-177 PSMA I&T and Lu-177 PSMA-617: Intra-individual comparison of kinetics and dosimetry	Christiane Schuchardt, THERANOSTICS Center for Molecular Radiotherapy and Molecular Imaging (PET/CT) , Zentralklinik Bad Berka GmbH, DE
39	188Re-HEDP and 188Re-Zoledronic acid for Palliative Treatment of Bone Metastases	Tatiana Kochetova, MRRC, RU
40	Lymph node metastases respond better than osseous metastases to treatment with Lu-177 labeled PSMA inhibitor in patients with metastatic castration-resistant prostate cancer	Harshad R. Kulkarni, THERANOSTICS Center for Molecular Radiotherapy and Molecular Imaging (PET/CT), DE
45	RGD: Biomarker for Angiogenesis as a Potential Theranostic Radiopharmaceutical	Rakhee Vatsa, PGIMER, IN
47	223Ra-dichloride treatment of bone metastases of patients with prostatic cancer: Efficacy and safety	Ildiko Garai, ScanoMed Ltd, University of Debrecen, HU
50	Role of Radiosynovectomy using Yttrium 90 in management of knee-joint bleeding in haemophilics, local experience in Syria	MAJDI ZEIN, Al-Assad university hospital-Damascus, SY
52	Improving radiosynoviorthesis using a Sn-117m colloid suspension	Knut Liepe, Klinikum Frankfurt (Oder), DE
55	Role of 64Cu-PSMA PET/CT in Theranostics of Prostate Cancer	Aviral Singh, Theranostics Center for Molecular Radiotherapy and Molecular Imaging, ENETS Center of Excellence, Zentralklinik Bad Berka, Germany, DE
65	Lu-177-Herceptin: A new radioimmunoconjugate for treatment of HER2 metastatic breast cancer	Priya Bhusari, PGIMER, Chandigarh, IN
67	SIRT for Liver Metastasis: Does tumoral dose influence time to progression: A comparison between the 99mTc- MAA workup and 90Y Bremsstrahlung imaging?	Kousigan Vadivelu, KIngs College London, IN

Poster ID	<b>Wednesday November 16</b>	
1	Comparison of Calibration Factors of Ra-223 in Commercial Radionuclide Dose Calibrators	Milena Dimcheva, Department of Nuclear Medicine, Sofia Cancer Center, BG
6	<sup>68</sup> Ga-labeled Magnetic Nanosheets of Graphene Oxide : a new Theranostic agent	Seyed Yousef Fazaeli Hoseini Nezhad, Nuclear science and Technology Research Institute (NSTRI), IR
10	graphene oxide/PVC nanocomposite; a new dosimeter for medical gamma radiation applications	Shahzad Feizi, Nuclear science and Technology Research Institute (NSTRI), IR
12	Survival and side effects rates of radionuclide therapy (RNT) of bone metastases by Sm-153 oxabifore (Sm-153) with different complex and combined regimes: chemo-, target, bisphosphonates and hormonal therapies.	Nigora Rasulova, Republic Specialized Center of Surgery, UZ
15	NETTER-1 Phase III in Patients with Midgut Neuroendocrine Tumors Treated with <sup>177</sup> Lu-Dotatate: Efficacy, Safety, QoL Results and Subgroup Analysis	Maribel Lopera Sierra, ADVANCED ACCELERATOR APPLICATIONS Inc., US
18	Peptide Receptor Radionuclide Therapy (LuDOTA) with Capacitabine and Temozolamide in Advanced Low Grade NeurendocrineTumor: A Dosimetry Evaluation	Vineet Pant, fortis memorial research institute, IN
19	Combined External and Internal Beam Radiotherapy (Combiert) for Inoperable Carotid Paraganglioma.	Vineet Pant, fortis memorial research institute, IN
24	THERAGNSOTICS OF PROSTATE CANCER IN MYANMAR: DREAM & FUTURE EXPECTATIONS	KYIN MYINT, MINISTRY OF HEALTH, MM
25	Tailor made Re-188 skin patch for radionuclide therapy of keloids	Jaya Shukla, Post Graduate Institute of Medical Education & Research, Chandigarh 160012, IN
30	Production and Therapeutic Application of Iodine- 131 in Nuclear Medicine of Bangladesh: Present status and Future Plan	Mohammad Anwar-Ul Azim, National Institute of Nuclear Medicine and Allied sciences, Bangladesh Atomic Energy Commission, Dhaka, BD
33	Assessment of Proton therapy & new proposed Plasma therapy on the view of Bragg effect	DR Tanvir Ahmed Biman, National Institute of Nuclear Medicine and Allied Sciences, Bangladesh Atomic Energy Commission, BD
37	Efficacy of Lu177-DOTATATE therapy for neuroendocrine tumours - our institutional experience.	Roni George Manjaly, Apollo hospitals, Chennai, Tamil Nadu-600006, IN
42	Validation studies of theranostic glycoconjugates in metastatic melanoma	Nilesh Wagh, Radiomedix inc, US
49	RADIONUCLIDIC DYE ANALOGUES FOR CANCER TARGETTING	DAYA HAZRA, INNOVATIVE CANCER THERAPY AND RESEARCH FOUNDATION,S N MEDICAL COLLEGE,AGRA, 282005, IN
54	Evaluation of Quality of Life After Each Cycle in Patients Treated with Peptide Receptor Radionuclide Therapy	IVY M VITO, ROYAL FREE LONDON NHS FOUNDATION TRUST, GB
61	FDG and <sup>68</sup> Ga-SSTR PET in the follow up of patients treated by PRRT:Where we are today	Bernhard Nilica, Medical University Innsbruck, Department for Nuclear Medicine, AT
66	Radioimmunoliposomes targeting cancer stem cells in mesothelioma	Jiang He, University of Virginia, US